KR-336 / Kernal Biologics - LARVOL DELTA

Systemically administered onco-selective mRNA LNP achieves tumor regression and improves overall survival, as monotherapy (SITC 2023) - "In a syngeneic MC38 tumor model, KR-336 was administered intravenously as a monotherapy, resulting in impressive anti-tumor effectiveness...Conclusions These findings collectively indicate the viability of systemic onco-selective mRNA LNP therapy as a potential treatment option for cancers characterized by an immunosuppressive tumor microenvironment. Additionally, it has the potential to drastically expand the patient population that can benefit from cancer immunotherapy."

Clinical • Monotherapy • Oncology • IFNG

Kernal Biologics to Present at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (PRNewswire) - "Kernal Biologics...announced it is presenting a poster at the Society for Immunotherapy of Cancer 2023 Annual Meeting on Friday, November 3, 2023 in San Diego, CA. The poster presentation features preclinical insights into KR-336, an onco-selective mRNA LNP therapeutic that Kernal Bio has rationally designed using their mRNA2.0 platform to be selectively translated into therapeutic protein within the tumor microenvironment....KR-336 data support use of onco-selective mRNA LNPs as a novel, promising modality for systemic immuno-oncology applications."

Preclinical • Oncology